Sequenom (SQNM) : Currently there are 3 street experts covering Sequenom (SQNM) stock. The most bullish and bearish price target for the stock is $2 and $1 respectively for the short term. The average price target of all the analysts comes to $1.35. The estimated standard deviation from the target is $0.91.
Sequenom (SQNM) has an average broker rating of 3, which is interpreted as a Hold, as rated by 4 equity analysts. Nevertheless, the majority of 4 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.
Sequenom (NASDAQ:SQNM): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $2.39 and $2.39 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $2.40. The buying momentum continued till the end and the stock did not give up its gains. It closed at $2.40, notching a gain of 0.42% for the day. The total traded volume was 613,866 . The stock had closed at $2.39 on the previous day.
Sequenom, Inc. (Sequenom) is a life sciences company. The Company serves patients and physicians by providing early patient management information. Its testing focus is principally in prenatal health that includes molecular-based laboratory developed tests (LDTs). The Companys diagnostic services are provided through its wholly owned subsidiary, Sequenom Laboratories. Sequenom Laboratories develops and validates its tests for use in, and by Sequenom Laboratories, as a testing service to physicians. Sequenom Laboratories is primarily focused on expanding the commercial use of, and reimbursement for its prenatal LDTs, and developing and offering a menu of tests for prenatal continuum of care. The Sequenom Laboratories test offerings in the prenatal market include MaterniT21 PLUS LDT, HerediT CF LDT, SensiGene RhD LDT, VisibiliT LDT and Test Send-out Agreements.